What changed: Thyroid cancer
Every dated change on the records linked to Thyroid cancer, newest first: approvals and regulatory steps on its medicines, trials that reported, guideline versions, milestones, and when this page itself was checked. Dates come from the records; none is inferred. Orientation, not medical advice.
Approval7Regulatory1Trial result6Milestone16This record1
September 2026 · 1
2026 · 1
2025 · 2
2023 · 1
2022 · 3
- 2022ApprovalDonafenibDonafenib approved in China
Radioiodine-refractory differentiated thyroid cancer
- 2022Trial resultESTIMABL2ESTIMABL2 reported
3-year event-free 95.
- 2022MilestoneESTIMABL2ESTIMABL2: no radioiodine for low-risk disease; ASTRA adjuvant redifferentiation negative
A milestone in how this cancer is treated.
2020 · 2
2019 · 1
2018 · 1
2015 · 2
2014 · 1
2013 · 3
- 2013ApprovalSorafenibSorafenib approved in US
Radioiodine-refractory differentiated thyroid cancer
- 2013Trial resultDECISIONDECISION reported
PFS 10.
- 2013MilestoneDECISIONSorafenib approved for RAI-refractory disease (DECISION); selumetinib redifferentiation proof of concept
A milestone in how this cancer is treated.
2012 · 3
2011 · 1
2009 · 1
2003 · 1
2000 · 1
1998 · 1
1985 · 1
1951 · 1
1946 · 3
- 1946RegulatoryRadioactive iodine (I-131)Radioactive iodine (I-131): approval (US)
First therapeutic use in thyroid cancer (Seidlin); formal approval followed
- 1946MilestoneRadioactive iodine (I-131)First patient treated with radioactive iodine for metastatic thyroid cancer
Seidlin, Marinelli, and Oshry: the first theranostic.
- 1946MilestoneThyroid cancerRadioactive iodine: first theranostic
A milestone in how this cancer is treated.